Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intercept's Revised NASH Trial Improves Prospects

Executive Summary

The pivotal REGENERATE study of Ocaliva now can succeed if either of two co-primary endpoints is achieved. Intercept also will use a new "objective" definition of NASH resolution in the study.


Related Content

Intercept Makes No Changes To Ocaliva NASH Study Despite PBC Safety Issues
Intercept's Ocaliva Seems Headed For Black Box On Liver Injury Risk
FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy
Intercept Increases Chance Of Success In NASH Without Significant Delay
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
Endpoint Selection Could Help Determine The NASH Race
The NASH Pipeline: Replete With Targets And New Compounds
'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim
NASH Drugs Soon May Have A Registrational Pathway, Finally
Searching For Surrogate Endpoints Requires Teamwork


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts